Westpac Banking Corp Sells 5,862 Shares of United Therapeutics Co. (UTHR)

Westpac Banking Corp decreased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 41.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,113 shares of the biotechnology company’s stock after selling 5,862 shares during the quarter. Westpac Banking Corp’s holdings in United Therapeutics were worth $1,037,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. BlackRock Inc. increased its holdings in shares of United Therapeutics by 2.3% in the 2nd quarter. BlackRock Inc. now owns 5,028,058 shares of the biotechnology company’s stock valued at $568,925,000 after acquiring an additional 115,073 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of United Therapeutics by 1.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,556,200 shares of the biotechnology company’s stock valued at $176,084,000 after acquiring an additional 22,322 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of United Therapeutics by 4.5% in the 3rd quarter. Acadian Asset Management LLC now owns 1,196,360 shares of the biotechnology company’s stock valued at $152,992,000 after acquiring an additional 51,346 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of United Therapeutics by 53.8% in the 3rd quarter. First Trust Advisors LP now owns 1,053,569 shares of the biotechnology company’s stock valued at $134,730,000 after acquiring an additional 368,613 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of United Therapeutics by 3.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 990,685 shares of the biotechnology company’s stock valued at $112,093,000 after acquiring an additional 32,611 shares during the last quarter. Institutional investors own 97.24% of the company’s stock.

In other United Therapeutics news, Director Christopher Causey sold 810 shares of the stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $118.00, for a total transaction of $95,580.00. Following the completion of the sale, the director now directly owns 3,925 shares of the company’s stock, valued at approximately $463,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.20% of the stock is owned by corporate insiders.

Shares of NASDAQ UTHR opened at $119.53 on Tuesday. The stock has a market capitalization of $5.15 billion, a P/E ratio of 10.98, a PEG ratio of 27.57 and a beta of 1.24. The company has a quick ratio of 4.05, a current ratio of 4.32 and a debt-to-equity ratio of 0.09. United Therapeutics Co. has a 52-week low of $100.57 and a 52-week high of $152.55.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.23 by ($0.81). The firm had revenue of $412.70 million during the quarter, compared to analyst estimates of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The firm’s revenue for the quarter was down 7.4% compared to the same quarter last year. During the same period last year, the company earned $4.69 earnings per share. As a group, research analysts forecast that United Therapeutics Co. will post 14.28 earnings per share for the current fiscal year.

A number of research analysts have recently commented on UTHR shares. Wedbush set a $253.00 price objective on United Therapeutics and gave the company a “buy” rating in a report on Thursday, September 27th. HC Wainwright set a $95.00 target price on United Therapeutics and gave the company a “hold” rating in a research report on Monday, August 13th. BidaskClub raised United Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. Cowen set a $106.00 target price on United Therapeutics and gave the company a “hold” rating in a research report on Wednesday, October 31st. Finally, Credit Suisse Group upped their target price on United Therapeutics from $103.00 to $105.00 and gave the company a “sell” rating in a research report on Monday, November 19th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. United Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $134.00.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/12/04/westpac-banking-corp-sells-5862-shares-of-united-therapeutics-co-uthr.html.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Story: S&P 500 Index

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit